Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Rhea-AI Summary

Editas Medicine (NASDAQ: EDIT) has announced it will release its Q4 and Full Year 2024 financial results and business updates on March 5, 2025, through a press release and SEC filings. The company has decided to discontinue hosting quarterly financial results conference calls.

The company's management team will participate in three major healthcare investor conferences in March: the TD Cowen 45th Annual Health Care Conference in Boston on March 3, the Leerink Partners Global Healthcare Conference in Miami on March 10, and the Barclays 27th Annual Global Healthcare Conference in Miami on March 11. All presentations will be in a fireside chat format and will be accessible via webcast on the company's website for approximately 30 days after each event.

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward.

Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March:

• TD Cowen 45th Annual Health Care Conference
  Format: Fireside Chat
  Date: Monday, March 3
  Time: 2:30 p.m. ET
  Location: Boston, MA

• Leerink Partners Global Healthcare Conference
  Format: Fireside Chat
  Date: Monday, March 10
  Time: 9:20 a.m. ET
  Location: Miami, FL

• Barclays 27th Annual Global Healthcare Conference
  Format: Fireside Chat
  Date: Tuesday, March 11
  Time: 9:00 a.m. ET
  Location: Miami, FL

To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

FAQ

When will Editas Medicine (EDIT) release its Q4 2024 earnings?

Editas Medicine will release its Q4 and Full Year 2024 financial results on March 5, 2025, through a press release and SEC filings.

Will Editas Medicine (EDIT) host a Q4 2024 earnings call?

No, Editas Medicine has announced it will no longer host quarterly financial results conference calls moving forward.

Which investor conferences will Editas Medicine (EDIT) attend in March 2025?

Editas Medicine will participate in three conferences: TD Cowen Health Care Conference (March 3), Leerink Partners Global Healthcare Conference (March 10), and Barclays Global Healthcare Conference (March 11).

How can investors access Editas Medicine's (EDIT) March 2025 conference presentations?

Investors can access the live webcasts through the 'Investors' section of Editas Medicine's website at www.editasmedicine.com. Replays will be available for approximately 30 days after each event.